Skip to main content

Table 2 Prevalence (95% Confidence Interval) of GFR Stages by MDRD and CKD-EPI equations, based on subjects with available serum creatinine and urine (N=1,098) in a randomly selected representative sample of the middle and older Irish population

From: Prevalence of diminished kidney function in a representative sample of middle and older age adults in the Irish population

  GFR Stage % (95% CI) Prevalence estimates N=1098 GFR Stage% (95% CI) Prevalence estimates N=1098
  MDRD CKD-EPI
GFR1 19.8% (17.4%, 22.1%) 34.4% (31.6%, 37.2%)
GFR 2 65.4% (62.6%, 68.2%) 53.8% (50.8%, 56.7%)
GFR3A 11.8% (9.9%, 13.7%) 9.2% (7.5%, 10.9%)
GFR3B 2.7% (1.8%, 3.7%) 2.3% (1.5%, 3.3%)
GFR 4-5 0.36% (0.07%, 0.7%) 0.36% (0.07%, 0.7%)
Total eGFR<60 14.9% (12.8%, 17%) 11.8% (9.9, 13.8)
Population Estimate (Weighted) eGFR<60 15.7% (12.7%, 18.7%) 11.6% (9.0%, 14.2%)
POPULATION PREVALENCE ESTIMATES OF CKD
CKD STAGES MDRD CKD EPI
CKD Stage 1 2.7% (1.9%, 3.9%) 3.8% (2.8%, 5.1%)
CKD Stage 2 7.2% (5.7%, 8.9%) 6.3% (4.9%, 7.9%)
CKD Stage 3A 11.8% (9.9%, 13.8%) 9.2% (7.5%, 10.9%)
CKD Stage 3B 2.7% (1.8%, 3.7%) 2.3% (1.5%, 3.3%)
CKD Stage 4-5 0.36% (0.07%, 0.7%) 0.36% (0.07%, 0.7%)
Total 24.8% (22.2%, 27.3%) 21.9% (19.5%, 24.4%)
Population Estimate CKD (Weighted) 25.1% (21.5%, 28.6%) 21.3% (18%, 24.6%)
  1. Population prevalence is estimated using both methods and inclusive of ACR>30mg/g for CKD Stage 1 and 2, using National Kidney Foundation criteria.